Primary Biliary Cholangitis
Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease in which the small bile ducts inside the liver are gradually damaged by the immune system. Over time, this can lead to bile buildup (cholestasis), inflammation, scarring (fibrosis), and—in some patients—cirrhosis and liver failure. PBC is most common in middle-aged women and is typically diagnosed through a combination of blood tests (including alkaline phosphatase and antimitochondrial antibodies) and—when needed—imaging or liver biopsy. With modern therapy, most patients have stable, well-controlled disease and a normal or near-normal life expectancy.
What is it?
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease in which the immune system mistakenly attacks and damages the small bile ducts within the liver. Over many years, this damage gradually impairs the flow of bile out of the liver, causing bile to back up within liver cells (cholestasis). The resulting injury leads to inflammation, scarring (fibrosis), and—in some patients—cirrhosis and complications of advanced liver disease. The disease was previously called “primary biliary cirrhosis,” but the name was updated to primary biliary cholangitis to better reflect the fact that most patients diagnosed today do not have cirrhosis, particularly with earlier detection and modern treatment.
The exact cause of PBC is not fully understood. It is generally considered an autoimmune disease that arises from a combination of genetic susceptibility and environmental triggers. PBC has a strong female predominance, with most cases occurring in middle-aged women, and tends to cluster within families, suggesting genetic contributions. Possible environmental triggers include infections, certain chemical exposures, and other factors that may stimulate the immune system in susceptible individuals.
PBC is the most common chronic autoimmune cholestatic liver disease in adults. It is often associated with other autoimmune conditions, including Sjögren syndrome (causing dry eyes and dry mouth), autoimmune thyroid disease, scleroderma, CREST syndrome, Raynaud phenomenon, celiac disease, and others. Some patients have overlap features with autoimmune hepatitis, which can affect both diagnosis and treatment.
Symptoms vary widely. Many patients with early PBC have no symptoms and are identified because of abnormal liver tests detected on routine bloodwork. As the disease progresses, the two most characteristic symptoms are fatigue and itching (pruritus). Fatigue is common and can be significant, sometimes affecting quality of life out of proportion to other features. Itching can range from mild and intermittent to severe and disabling and is thought to be related to substances that accumulate when bile flow is impaired. Other possible symptoms include dry eyes and dry mouth (often related to associated Sjögren syndrome), upper right abdominal discomfort, fatty stools (steatorrhea) from impaired fat absorption, deficiencies in fat-soluble vitamins (A, D, E, K), joint pain, and yellowish skin or eye discoloration (jaundice) in more advanced disease. Some patients develop yellowish cholesterol deposits on the eyelids (xanthelasma) or skin (xanthoma) related to elevated cholesterol levels. As disease advances and progresses to cirrhosis, complications of portal hypertension—such as variceal bleeding, ascites, and hepatic encephalopathy—can develop.
Diagnosis of PBC is generally made by a combination of clinical features and laboratory tests, with imaging or biopsy used to confirm the diagnosis or exclude other conditions. The classic laboratory pattern is a “cholestatic” picture, with elevated alkaline phosphatase and gamma-glutamyl transferase, often with normal or only modestly elevated AST and ALT. Antimitochondrial antibodies (AMA) are present in the great majority of patients with PBC and are highly specific. A subset of patients have AMA-negative PBC, in which other antibodies—such as anti-sp100 and anti-gp210—may be helpful. Elevated IgM levels are common.
Abdominal ultrasound is generally used to evaluate the liver and biliary tree and to exclude other causes of cholestasis, such as bile duct obstruction. MRI with MR cholangiopancreatography (MRCP) is particularly useful when imaging is needed to evaluate the larger bile ducts and to rule out primary sclerosing cholangitis, biliary stones, and other conditions. Elastography (such as FibroScan or MR elastography) helps assess liver stiffness as a marker of fibrosis. Liver biopsy is not always required when typical clinical, laboratory, and serologic features are present but may be considered when the diagnosis is uncertain, when an overlap syndrome is suspected, or when staging is needed.
Important to Know
Management of PBC focuses on slowing disease progression, controlling symptoms, monitoring for complications, and providing appropriate treatment for associated conditions. With modern care, most patients have stable, well-controlled disease and live a normal or near-normal lifespan.
Ursodeoxycholic acid (UDCA) is the first-line treatment for PBC and has substantially changed the outlook of the disease. Most patients respond well to UDCA, with improvement in liver tests, slowing of disease progression, and reduction in the risk of cirrhosis and liver-related complications. UDCA is generally taken long-term and is well tolerated by most patients.
For patients who do not respond adequately to UDCA, several second-line options are available. Obeticholic acid is a bile acid–related medication that can improve liver tests and clinical course in selected patients, although it requires careful dose adjustment and monitoring, particularly in patients with more advanced disease. Fibrates—such as bezafibrate and fenofibrate—have shown benefit in selected patients with inadequate response to UDCA and are used in many centers, particularly in regions where bezafibrate is available. Newer agents, including PPAR agonists, are increasingly entering practice and are expanding treatment options. The choice between second-line treatments depends on individual response, stage of disease, side effects, and availability.
Symptom-directed treatment is an important part of care. Itching can be managed with measures such as cholestyramine and other bile acid–binding resins, rifampin, naltrexone, sertraline, light therapy, and—in some centers—newer medications. Severe, refractory itching may significantly affect quality of life and sometimes leads to consideration of additional treatments. Fatigue is harder to treat directly, but addressing sleep, exercise, mental health, and any reversible contributors (such as anemia, thyroid disease, or sleep apnea) often helps. Dry eyes and dry mouth are managed with lubricants, saliva substitutes, and other measures, often in collaboration with rheumatology or ophthalmology.
Nutritional and bone health management is important. Patients with significant cholestasis may have impaired absorption of fat and fat-soluble vitamins (A, D, E, K) and may need supplementation. Bone health is a particular concern in PBC, and screening for osteoporosis with bone density testing, along with calcium, vitamin D, and—when needed—specific osteoporosis treatments, is recommended. Lipid abnormalities are common and are managed in coordination with cardiovascular risk assessment; statins can usually be used safely in PBC when indicated.
Monitoring for complications of advanced disease and cancer is essential. Patients with significant fibrosis or cirrhosis benefit from screening for varices (typically with endoscopy) and periodic surveillance for hepatocellular carcinoma. Vaccinations against hepatitis A and B, influenza, pneumococcal infection, COVID-19, and other infections are important.
Liver transplantation is the ultimate treatment for advanced PBC and is considered in patients with end-stage liver disease, refractory complications of cirrhosis, or—in selected cases—severe and disabling itching that does not respond to medical therapy. Outcomes after transplantation for PBC are generally excellent, although recurrence of PBC in the transplanted liver can occur over time.
Care is typically coordinated by hepatologists or gastroenterologists with experience in PBC, primary care clinicians, and, when relevant, rheumatologists (for associated autoimmune diseases), ophthalmologists, endocrinologists, dietitians, and other specialists.
Red flag symptoms include severe persistent abdominal pain, rapidly progressive jaundice, vomiting blood or coffee-ground material, black or tarry stools, severe abdominal swelling or shortness of breath, severe lethargy or confusion, significant unintentional weight loss, severe leg swelling, signs of severe infection, or sudden, severely disabling itching. These warrant prompt or urgent medical evaluation, as they may indicate complications of advanced liver disease, infection, or other serious conditions.